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N=3,054 patients were identified as participants
N=200 patients were included in this study
Table 1. Baseline clinical and demographic characteristics of study population.
 ≥18 years of age
 Diagnosis of HIV-1
 Treatment-naïve, or no ART for >6 months
 Initiated on ART between January 2013 – January 2018
 Maintained therapy ≥24 months
 Wt. values recorded at least twice during the study period
 Were initiated on any 3-drug regimen containing the 
following: NNRTIs, NRTIs, INSTIs, PIs, +/- PK boosters
METHODS
BACKGROUND RESULTS
REFERENCES
DISCLOSURES
Integrase strand transfer inhibitor 
(INSTI) based regimens play a 
pivotal role in ART for treatment-
naïve individuals, and are 
recommended for first line 
therapy in the adult US 
Department of Health & Human 
Services (DHHS) guidelines1
Existing research has observed a 
potential association between 
antiretroviral therapy exposed 
individuals and a high prevalence 
of weight gain and obesity2,3,4,5
Uncertainty lies within the 
differences in the prevalence of 
weight gain between the different 
classes of ART agents, 
particularly in treatment-naïve 
individuals with HIV-12,3,4,5
For patients infected with HIV-1, 
antiretroviral therapy (ART) has 
shown positive impact on 
immunologic recovery & survival1,4
The primary objective of this study is to evaluate weight change in 
treatment-naïve patients with newly initiated ART in a Ryan White Clinic
Inclusion
 Age, gender, ethnicity, AIDS status (CD4+ T-cell count 
<200μL/mL), Plasma HIV-1 RNA (viral load), ART regimen, 
weight (kg), BMI (kg/m2), BMI Category, Plasma HIV-1 RNA 
(viral load), and CD4+ T-cell count by ART class (NNRTI, 
PI, INSTI) at baseline
Baseline
Characteristics
 Women participants who became pregnant at any point 
during the study period
 Patients currently on ART, or who have been on ART within 
the previous 6 monthsExclusion
 Weight (kg), BMI (kg/m2), BMI Category, Plasma HIV-1 
RNA (viral load), and CD4+ T-cell count by ART class 
(NNRTI, PI, INSTI) within 6 months of ART initiation
 Weight (kg), BMI (kg/m2), BMI Category, Plasma HIV-1 
RNA (viral load), and CD4+ T-cell count by ART class 
(NNRTI, PI, INSTI) within 18 months of ART initiation
Outcomes
Assessed
CONCLUSIONS
Treatment naïve patients with HIV-1 initiating therapy with 
dolutegravir-based regimens were associated with a higher 
incidence of increase in weight and BMI at 18-months than 
those initiating elvitegravir, NNRTI, and PI-based regimens. 
1
Those initiating raltegravir-based regimens, all of which 
also contained concomitant darunavir/r, were associated 
with the highest incidence of increase in weight and 
BMI and 18-months than all other regimens. 
2
Further research is recommended.
Baseline 
Demographics
All Regimens
(N=200)
NNRTI
(N=42)
PI
(N=50)
INSTI
(N=113)
DTG
(N=82)
EVG
(N=25)
RAL
(N=6)
Age (years) 38.3 38.6 42.2 37.0 35.9 38.2 48.2
Caucasian 110 (55.0%) 31 (73.8%) 23 (46.0%) 56 (49.6%) 39 (47.6%) 15 (60.0%) 2 (33.3%)
Male Sex 162 (81.0%) 38 (90.5%) 38 (76.0%) 90 (79.6%) 69 (84.1%) 16 (64.0%) 4 (66.6%)
CD4+ T-Cell 
Count (cells/μL)
356.2 335.6 249.4 405.5 406.3 411.0 372.3
CD4+ T-Cell 
Percent (%)
19.3 20.2 15.4 20.2 20.1 21.5 12.5
AIDS Status
(CD4+ <200 
cells/μL)
70 (35%) 14 (33.3%) 27 (54.0%) 33 (29.2%) 24 (29.3%) 7 (28.0%) 2 (33.3%)
HIV-1 RNA 
(copies/mL)
481,801 1,203,633 1,324,345 201,308 216,236 180,125.2 85,558
HIV-1 RNA
>100,000
(copies/mL)
74 (37.0%) 19 (45.2%) 23 (46.0%) 38 (33.6%) 27 (29.3%) 9 (36.0%) 2 (33.3%)
Weight (kg) 80.8 75.9 78.9 84.1 85.9 76.8 90.9
BMI (kg/m2) 26.2 24.8 25.8 27.1 27.1 26.3 30.1
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Figure 1. Weight change by ART class within: 
(A) 6-months of ART initiation, and 
(B) 18-months of ART initiation
Figure 2. BMI change by ART class within: 
(A) 6-months of ART initiation, and 
(B) 18-months of ART initiation
+3.3 kg +2.2 kg
Regimens of Patients on Raltegravir (N=6)
Patient 1) Raltegravir / Darunavir / Zidovudine / Lamivudine / Ritonavir
Patient 2) Raltegravir / Darunavir / Etravirine / Ritonavir
Patient 3) Raltegravir / Darunavir / Zidovudine / Ritonavir
Patient 4) Raltegravir / Darunavir / Emtricitabine / Tenofovir DF / Ritonavir
Patient 5) Raltegravir / Darunavir / Etravirine / Ritonavir
Patient 6) Raltegravir / Darunavir / Ritonavir
FURTHER ANALYSIS
